Considerations for the development of therapeutic monoclonal antibodies. - Wikidata - awgldk - TriplyDB

Considerations for the development of therapeutic monoclonal antibodies.

Considerations for the development of therapeutic monoclonal antibodies.

http://www.wikidata.org/entity/Q37202228

about

mAbs: a business perspective Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance Improving biophysical properties of a bispecific antibody scaffold to aid developability Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions A novel antibody humanization method based on epitopes scanning and molecular dynamics simulation Mining human antibody repertoires.Capturing the natural diversity of the human antibody response against vaccinia virus Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys Antibody-based therapy of leukaemia.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Review on modeling anti-antibody responses to monoclonal antibodies.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use.Epitope analysis of the rat dipeptidyl peptidase IV monoclonal antibody 6A3 that blocks pericellular fibronectin-mediated cancer cell adhesion.Computationally driven antibody engineering enables simultaneous humanization and thermostabilization.Biosimilars 2.0: guiding principles for a global "patients first" standard.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.Construction and characterization of a novel chimeric antibody c3C7 specific for the integrin αIIbβ3 complex.

P2860

Q24653360-6B21C210-C3AB-4EC1-A137-DB5078625BE3 Q26747193-5F251108-2DF8-4984-8A19-C15241C08A65 Q27679445-8801B70D-0084-4B14-AB0D-CD6DBB3D3D66 Q28539968-DE5815D4-CD68-447D-A07E-38A9C8E97D81 Q31144470-723451DE-50FB-4866-BA50-F21279B9F5BC Q33588489-4E185578-BEFF-49EC-98ED-82F0EC9AB233 Q34529713-FE846189-923A-42F1-9C52-50F624AF51D8 Q35149457-B87BBA27-025D-4442-AC96-4AA02C9016A2 Q35888359-C83B3EC1-A06B-407A-BF62-AD904324A792 Q37295534-DF9F5B70-7906-48E2-890F-868B95ED4548 Q37605247-C5260B8D-8118-407F-BF4F-A51C32A1BD8E Q37854644-27B59D79-5E2E-4952-8092-D778BBAE0C94 Q38229813-BA233B17-D2E3-4737-88B2-26F81E145288 Q38364547-3C8EE0B1-5578-4F21-9C2E-CC9D4B880C97 Q39558396-9D9062B2-8592-4172-A035-3B4869A0E18D Q39791473-3002EB41-67D8-41B2-B02C-D9B273FE39F9 Q41656698-87A1AA1E-C81E-4184-B842-493EAB870498 Q41835516-128F1B8C-7416-4342-AB64-73E1D9FE4CC5 Q42869354-D962B818-4675-4BC4-8824-FBEB3927BA50 Q43072108-7CB145A0-E7E2-4AFE-A23B-EB4846DF4909 Q51021473-C1AD574C-D58B-44DB-9A63-2D88A1ED8CA7 Q51751592-224B4AEC-23DE-40B1-9825-1C9BE33E37B3

P2860

Considerations for the development of therapeutic monoclonal antibodies.

http://www.wikidata.org/entity/Q37202228

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Considerations for the development of therapeutic monoclonal antibodies.

@en

Considerations for the development of therapeutic monoclonal antibodies.

@nl

type

label

Considerations for the development of therapeutic monoclonal antibodies.

@en

Considerations for the development of therapeutic monoclonal antibodies.

@nl

prefLabel

Considerations for the development of therapeutic monoclonal antibodies.

@en

Considerations for the development of therapeutic monoclonal antibodies.

@nl

P1433

Q37202228-449C4D27-1A41-4954-A43A-300D0901CA81

P1476

Q37202228-7F5B5027-8F9C-41B9-9060-73D5B3749F77

P2093

Q37202228-96261AFF-647A-4E0C-B651-2843997C0123

Q37202228-984C8BE7-268A-4A00-AF7F-97F2CAB37082

Q37202228-A057C739-F8C8-4B8D-9396-99A66FB7D10B

Q37202228-ABCEDD52-AB07-4294-9D93-C1760F98C5ED

Q37202228-CB5ADBA4-2AA6-4776-9DCD-485F1E460549

Q37202228-EDE6BC1C-BB1C-40F4-A503-7C162A1A78BE

P304

Q37202228-BB26EA26-9ED7-4E8B-A5A3-DE4C8B743993

P31

Q37202228-3DA00E9D-1216-402B-BAE9-2304B2BC91D4

P356

Q37202228-CB4D9F9A-9B75-4BA8-AD47-B7AE53B62818

P433

Q37202228-459AA0BC-DF9F-442B-BE4E-A35E6A1E4142

P478

Q37202228-D4CF8006-E1AF-498B-AB9F-3FD6EEE10D77

P577

Q37202228-DF2EA930-4F92-4901-8E1E-6112E0972629

P5875

Q37202228-5F72FD6B-44C5-4C03-A87E-2336569C498E

P698

Q37202228-E07C5BAD-A82A-43D8-B407-D40898F616C3

P921

Q37202228-70F106A3-79A0-4EDF-BBCF-FA2A09F1F7D3

P356

J.COI.2008.05.013

P1433

Current Opinion in Immunology

P1476

Considerations for the development of therapeutic monoclonal antibodies.

@en

P2093

Barbara L Rellahan

http://www.w3.org/2001/XMLSchema#string

Kathleen A Clouse

http://www.w3.org/2001/XMLSchema#string

Marjorie A Shapiro

http://www.w3.org/2001/XMLSchema#string

Mate Tolnay

http://www.w3.org/2001/XMLSchema#string

Patrick G Swann

http://www.w3.org/2001/XMLSchema#string

Subramanian Muthukkumar

http://www.w3.org/2001/XMLSchema#string

P304

493-499

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COI.2008.05.013

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5270108

http://www.w3.org/2001/XMLSchema#string

P698

18586093

http://www.w3.org/2001/XMLSchema#string

P921